Level D· Scientific groundwork from lab and animal studiesNarrative ReviewPubMed

Molecular and cellular mechanisms of muscle-adipose tissue crosstalk driving sarcopenic obesity: an integrative review of human, animal, and in vitro models.

Seliem MA., Ragab MA.

Narrative Review on Type 2 Diabetes, published in Nutr Metab (Lond) (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Nutr Metab (Lond) (2026)
Country
England
Reported sample size
—
Source database
PubMed
PMID
42129838
DOI
10.1186/s12986-026-01123-2

Abstract (original English)

Sarcopenic Obesity is a complex geriatric syndrome that is not simply the co-occurrence of sarcopenia and obesity but is a synergistic pathophysiological relationship in which the sum of the risk factors is greater than the sum of the individual conditions. This integrative review proposes that sarcopenic obesity is fundamentally an illness of impaired bidirectional communication between skeletal muscle and adipose tissue that function as dynamic endocrine organs that interact through a vast repertoire of bioactive molecules. We critically analyze the molecular signaling pathways responsible for this crosstalk and the simultaneous hyperactivation of the Ubiquitin-Proteasome System and NF-κB pathways. Furthermore, highlighting the paradigm-shifting role of the Exosomal miRNA Regulatory Network, we explored how adipose-derived extracellular vesicles deliver atromiRs (e.g., miR-27a, Let-7d-3p) to myocytes and cause insulin resistance and regenerative failure, and the loss of myocyte-derived miR-146a-5p eliminates an important brake on adipogenesis. Also, we explored cellular mechanisms such as macrophage phenotypic switching (metaflammation), mitochondrial lipotoxicity, and the newly emerging gut-microbiota-muscle axis. Finally, we explored advanced experimental models, such as organ-on-a-chip systems, and explored the clinical paradox of GLP-1 receptor agonist-induced muscle loss

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research